dasotraline + Placebo

Phase 3Completed

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Attention-Deficit Hyperactivity Disorder (ADHD)

Conditions

Attention-Deficit Hyperactivity Disorder (ADHD)

Trial Timeline

Jul 31, 2017 → Mar 15, 2019

NCT ID

NCT03231800

About dasotraline + Placebo

dasotraline + Placebo is a phase 3 stage product being developed by Sumitomo Pharma for Attention-Deficit Hyperactivity Disorder (ADHD). The current trial status is completed. This product is registered under clinical trial identifier NCT03231800. Target conditions include Attention-Deficit Hyperactivity Disorder (ADHD).

What happened to similar drugs?

8 of 12 similar drugs in Attention-Deficit Hyperactivity Disorder (ADHD) were approved

Approved (8) Terminated (0) Active (4)

✅atomoxetineEli LillyApproved

✅AtomoxetineEli LillyApproved

🔄dasotraline 4mgSumitomo PharmaPhase 3

✅Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR) + PlaceboNovartisApproved

✅SPN-812Supernus PharmaceuticalsApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03231800	Phase 3	Completed	Jul 31, 2017	Mar 15, 2019	Attention-Deficit Hyperactivity Disorder (ADHD)
NCT02564588	Phase 2/3	Completed	Oct 1, 2015	Oct 1, 2016	Binge Eating Disorder

Competing Products

20 competing products in Attention-Deficit Hyperactivity Disorder (ADHD)

See all competitors

Product	Company	Stage	Hype Score
atomoxetine	Eli Lilly	Approved	39
Atomoxetine	Eli Lilly	Approved	43
Atomoxetine	Eli Lilly	Approved	43
Atomoxetine	Eli Lilly	Approved	43
dasotraline 4mg	Sumitomo Pharma	Phase 3	40
ABT-089 + atomoxetine + placebo	AbbVie	Phase 2	35
ABT-089 + Placebo	AbbVie	Phase 2	35
ABT-089	AbbVie	Phase 2	35
ABT-089 + placebo	AbbVie	Phase 2	35
MK0249 + Concerta (methylphenidate) + Placebo	Merck	Phase 2	35
Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR) + Placebo	Novartis	Approved	43
SPN-812	Supernus Pharmaceuticals	Approved	37
IR Viloxazine + Placebo	Supernus Pharmaceuticals	Phase 1/2	26
SPN-812	Supernus Pharmaceuticals	Approved	37
100mg SPN-812 + Placebo	Supernus Pharmaceuticals	Approved	44
SPN-812	Supernus Pharmaceuticals	Phase 3	34
Placebo + SPN-812	Supernus Pharmaceuticals	Phase 3	34
Placebo + 100mg SPN-812 + 200mg SPN-812 + 300mg SPN-812 + 400mg SPN-812	Supernus Pharmaceuticals	Phase 2	29
SPN-812	Supernus Pharmaceuticals	Phase 3	38
TD-9855 + TD-9855 + Placebo	Theravance Biopharma	Phase 2	29